ConductScience.org, home

Paper896122

Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases.

Maness PF and 1 other. Oncology, 1977. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases. Papers, record 896122. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/896122

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases.
PubMed
Journal
Oncology
PubMed
Year
1977
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
0.45
iCite
Revised in PubMed
2018-02-16
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Maness PFP F
2Orengo AA

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Colonic NeoplasmsMajor topic
Complement System ProteinsMajor topic
NeoplasmsMajor topic
Stomach NeoplasmsMajor topic
Adenocarcinoma
Esophageal Neoplasms
Female
Humans
Male
Sex Factors

Source PubMed

Download CSV of topics

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
41526546The contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia and acute myelogenous leukemia.Sci Rep2026https://conductscience.org/library/papers/41526546PubMed
37357623Complement system in Anti-CD20 mAb therapy for cancer: A mini-review.Int J Immunopathol Pharmacol2023https://conductscience.org/library/papers/37357623PubMed
27043541Identification of Serum Peptidome Signatures of Non-Small Cell Lung Cancer.Int J Mol Sci2016https://conductscience.org/library/papers/27043541PubMed
24272362The role of complement in tumor growth.Adv Exp Med Biol2014https://conductscience.org/library/papers/24272362PubMed
23706991Complement inhibition in cancer therapy.Semin Immunol2013https://conductscience.org/library/papers/23706991PubMed
17030172Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors.Gastroenterology2006https://conductscience.org/library/papers/17030172PubMed
7379328Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease.Clin Exp Immunol1980https://conductscience.org/library/papers/7379328PubMed
109056Nutritional status and the nonspecific cellular and humoral immune response in esophageal carcinoma.Ann Surg1979https://conductscience.org/library/papers/109056PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/896122

GET https://conductscience.org/api/papers/v1/896122/authors